Introducing clinical pharmacy services to cardiovascular clinics at a university hospital in Northern Cyprus
- 272 Downloads
Background Clinical pharmacists are the primary source of scientifically valid information and advice on the safe, rational, and cost-effective use of medications. However, ward-based clinical pharmacy services are not well optimized in Northern Cyprus. Objective Ward based clinical pharmacy services were introduced and evaluated in cardiovascular clinics. Setting Cardiology and cardiovascular surgery departments in a tertiary university hospital. Methods A prospective interventional study introduced and documented clinical pharmacy services for 120 days. Drug-related problems were classified using the Pharmaceutical Care Network Europe PCNE DRP classification tool V6.2. Main outcome measure Interventions proposed and acceptance rate of recommendations. Results A total of 133 patients were reviewed, and, 81 patients had drug-related problems. Only 402 (93.1%) of the 432 suggested interventions were accepted and regarded as clinically relevant. Drug-related problems primarily involved antihypertensive, diuretic, and antithrombotic agents. Treatment effectiveness was the major type of drug-related problems (107; 49.3%) followed by adverse drug reactions (74; 34.1%). Drug dose and selection were the most frequent causes of drug-related problems. Add/change/stop medications were the most common types of intervention at the prescriber level. A total of 171 (78.8%) of the identified 217 drug-related problems were solved, 4 (1.8%) of the problems were partially solved, 32 (14.7%) problems were unsolved, and 10 (4.6%) problems had unknown outcomes. Conclusion Clinical pharmacy services may have optimized therapy effectiveness and prevent adverse effects. The pharmacist interventions were highly accepted by cardiologists; this may indicate the presence of a great opportunity and need to optimize and implement CPS in other hospitals in Northern Cyprus.
KeywordsCardiology Clinical pharmacy services Cyprus Drug-related problems PCNE Pharmaceutical care
The authors are grateful to Rani Dabal, Dr. Bahaaldeen Al-Baghdadi, Dr. Aiser Hassan, Dr. Falahaldeen Al-Baghdadi, and Dr. Roua Dabal for their support and encouragement.
Conflicts of interest
- 1.WHO. Cardiovascular diseases (CVDs). World Health Organization. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed 24 Dec 2016.
- 2.WHO. NCD country profile 2014: Cyprus. World Health Organization. http://www.who.int/nmh/countries/cyp_en.pdf. Accessed 05 Mar 2017.
- 5.American College of Clinical Pharmacy. The strategic plan of the American College of Clinical Pharmacy, 1993. Pharmacotherapy. 1993;13(3):257–61.Google Scholar
- 11.Europe PCN. DRP-Classification V6.2. January 14, 2010. Pharmaceutical care network Europe. http://www.pcne.org/upload/files/11_PCNE_classification_V6-2.pdf. Accessed 15 Dec 2016.
- 15.Europe PCN. Pharmaceutical care network Europe. http://www.pcne.org/. Accessed 15 Dec 2016.
- 17.Kováčová B, Hasilla J, Ďurišová A. Medication review in inpatients at cardiology clinic/Prehodnotenie terapie u hospitalizovaných pacientov na kardiologickej klinike. Acta Facultatis Pharmaceuticae Universitatis Comenianae. 2015;62(1):15–9.Google Scholar
- 18.Abraham RR. Drug related problems and reactive pharmacist interventions for inpatients receiving cardiovascular drugs. Int J Basic Med Sci Pharm (IJBMSP). 2014;3(2):42–8.Google Scholar
- 21.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52.CrossRefPubMedGoogle Scholar